STOCK TITAN

Kura Oncology insider files Form 144 for 12,314-share PSU sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Kura Oncology Form 144 notice reporting a proposed sale of 12,314 shares of common stock. The filer intends to sell the shares through Morgan Stanley Smith Barney LLC on NASDAQ around 09/29/2025, with an aggregate market value listed at $111,441.70. The shares were acquired two days earlier on 09/27/2025 as performance stock units (PSUs) issued by the company and are to be paid/settled on 09/29/2025. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider sale of recently issued PSUs, small relative to outstanding shares; appears procedural rather than market-moving.

The notice documents a proposed sale of 12,314 common shares acquired as performance stock units two days prior to the intended sale. At an aggregate value of $111,441.70 against 87,015,518 shares outstanding, the transaction represents a de minimis portion of the capital base. The timing—immediate post-issuance settlement—and the seller's attestation of no undisclosed material information suggest a routine disposition of vested compensation rather than a sale prompted by company-specific adverse developments. No other recent sales by the same person are reported.

TL;DR: Filing documents compliant Rule 144 sale of PSUs; disclosure is standard and contains required attestations.

The Form 144 provides required broker, share count, acquisition method (PSU), and settlement timing. The broker identified is Morgan Stanley Smith Barney LLC and the planned execution venue is NASDAQ. The signer makes the statutory representation about lack of undisclosed material information and the form indicates no aggregated prior sales. From a governance and compliance perspective, the filing meets procedural requirements for public disclosure of an insider sale tied to compensation vesting.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did KURA's Form 144 report on proposed sales?

The filing reports a proposed sale of 12,314 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, planned for 09/29/2025, with aggregate market value $111,441.70.

What was the acquisition type and date for the shares in the KURA filing?

The shares were acquired as performance stock units (PSUs) on 09/27/2025 from the issuer.

Does the KURA Form 144 show other recent sales by the same person?

No. The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker and exchange are listed in the KURA Form 144?

The broker is Morgan Stanley Smith Barney LLC and the exchange named is NASDAQ.

Is there any assertion about undisclosed material information in the filing?

Yes. The filer represents by signature that they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.
Kura Oncology Inc

NASDAQ:KURA

KURA Rankings

KURA Latest News

KURA Latest SEC Filings

KURA Stock Data

746.61M
84.34M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO